314 related articles for article (PubMed ID: 21725372)
21. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T
Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373
[TBL] [Abstract][Full Text] [Related]
22. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies.
Jantunen E; Kvalheim G
Eur J Haematol; 2010 Dec; 85(6):463-71. PubMed ID: 20738393
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
24. Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G; Vanazzi A; Radice D; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
[TBL] [Abstract][Full Text] [Related]
25. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
[TBL] [Abstract][Full Text] [Related]
27. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
Flomenberg N; Comenzo RL; Badel K; Calandra G
Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
[TBL] [Abstract][Full Text] [Related]
28. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
30. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Micallef IN; Stiff PJ; DiPersio JF; Maziarz RT; McCarty JM; Bridger G; Calandra G
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1578-86. PubMed ID: 19896082
[TBL] [Abstract][Full Text] [Related]
31. An updated single center experience with plerixafor and granulocyte colony-stimulating factor for stem cell mobilization in light chain amyloidosis.
Badar T; Dhakal B; Szabo A; Padmanabhan A; Johnson BD; Heidtke S; Esselmann J; Chhabra S; Hamadani M; Hari P; D'Souza A
J Clin Apher; 2019 Dec; 34(6):686-691. PubMed ID: 31566813
[TBL] [Abstract][Full Text] [Related]
32. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Brave M; Farrell A; Ching Lin S; Ocheltree T; Pope Miksinski S; Lee SL; Saber H; Fourie J; Tornoe C; Booth B; Yuan W; He K; Justice R; Pazdur R
Oncology; 2010; 78(3-4):282-8. PubMed ID: 20530974
[TBL] [Abstract][Full Text] [Related]
33. Plerixafor: what we still have to learn.
Lanza F; Gardellini A; Laszlo D; Martino M
Expert Opin Biol Ther; 2015 Feb; 15(2):143-7. PubMed ID: 25315706
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.
Yannaki E; Karponi G; Zervou F; Constantinou V; Bouinta A; Tachynopoulou V; Kotta K; Jonlin E; Papayannopoulou T; Anagnostopoulos A; Stamatoyannopoulos G
Hum Gene Ther; 2013 Oct; 24(10):852-60. PubMed ID: 24001178
[TBL] [Abstract][Full Text] [Related]
36. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
Haverkos BM; Huang Y; Elder P; O'Donnell L; Scholl D; Whittaker B; Vasu S; Penza S; Andritsos LA; Devine SM; Jaglowski SM
Bone Marrow Transplant; 2017 Apr; 52(4):561-566. PubMed ID: 28067870
[TBL] [Abstract][Full Text] [Related]
37. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L; Laszlo D; Rizzi S; Balzarotti M; Antoniazzi F; Zilioli VR; Guggiari E; Farina L; Todisco E; Bonfichi M; Alamos SM; Rossi G; Martinelli G; Morra E
Leuk Res; 2011 Jun; 35(6):712-4. PubMed ID: 21276613
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
39. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
40. HIF-1α is required for hematopoietic stem cell mobilization and 4-prolyl hydroxylase inhibitors enhance mobilization by stabilizing HIF-1α.
Forristal CE; Nowlan B; Jacobsen RN; Barbier V; Walkinshaw G; Walkley CR; Winkler IG; Levesque JP
Leukemia; 2015 Jun; 29(6):1366-78. PubMed ID: 25578474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]